Introduction
Allele’s iPSC division consistently expands its off-the-shelf cGMP iPSC library, adding six new lines every three months from two donors, with flexibility to adjust production based on market demand. This approach ensures partners can compare multiple cell lines before committing to product development.
The streamlined process includes a testing phase where partners access and evaluate cell lines for specific workflows, with optional preclinical animal model testing to strengthen investor confidence. Customized licensing agreements follow, tailored to include exclusivity, application fields, market territories, and flexible financial terms like upfront payments, milestones, and royalties.
Features / strengths
* End-to-End cGMP Compliance since 2016.
* Reproducible > 400 runs
* Highest Safety Profile achieved by Allele's patented mRNA reprogramming technology.
* Genome footprint-free, Viral element-free, Xeno free
* Demonstrated Differentiation Potentials
* cGMP iPSC lines guarantee exceptional stability and long-term production success.
*cGMP iPSC Rigorous Quality Control
Specification in detail
Regulatory Standard
cGMP (current Good Manufacturing Practice)
Safety
FDA Approved, AABB accredited
